Idexx Reaches New 52-Week High (IDXX)

NEW YORK ( TheStreet) -- Idexx Laboratories (Nasdaq: IDXX) hit a new 52-week high Tuesday as it is currently trading at $89.50, above its previous 52-week high of $89.50 with 108,287 shares traded as of 12:34 p.m. ET. Average volume has been 253,900 shares over the past 30 days.

Idexx has a market cap of $4.85 billion and is part of the health care sector and drugs industry. Shares are up 14.3% year to date as of the close of trading on Monday.

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. The company has a P/E ratio of 30.6, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Idexx as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, increase in net income, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Idexx Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

Arconic, Idexx Laboratories, AbbVie: 'Mad Money' Lightning Round

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

Resist All the Dow 22K Hoopla: Cramer's 'Mad Money' Recap (Wednesday 8/2/17)

IDEXX Laboratories: Cramer's Top Takeaways

'I Love the Down-and-Outers': Cramer's 'Mad Money' Recap (Thursday 7/13/17)